Connect with us

Technology

Exubrion Therapeutics® Appoints Jennifer Kirk to Board of Directors; Names Her CEO

Published

on

ALPHARETTA, Ga., March 18, 2025 /PRNewswire/ — Exubrion Therapeutics, the pioneering company behind Synovetin OA®, an innovative injectable treatment that provides relief for dogs suffering from chronic osteoarthritis, announced today that Jennifer Kirk has been appointed to the company’s Board of Directors and will assume the role of Chief Executive Officer effective May 3, 2025. Synovetin OA utilizes proprietary radiotherapeutic technology to deliver targeted, localized relief, helping dogs regain mobility and live pain-free for up to one year after a single treatment.

Kirk brings more than 28 years of leadership and business transformation experience, including a successful tenure at Medtronic, one of the world’s leading medical technology companies. While at Medtronic, she held key executive leadership roles focusing on finance and operational growth. Her experience navigating complex, high-growth organizations in medtech and other industries uniquely positions her to lead Exubrion Therapeutics.

“We are thrilled to welcome Jennifer to the Exubrion Therapeutics leadership team,” said Laurie McRay, Executive Chair and interim CEO. “Her energy, servant leadership, and extensive business experience make her the ideal person to guide us into our next phase of growth. Her proven ability to lead organizations and create value will be instrumental as we continue advancing our mission. We are fortunate to have her at the helm.”

Throughout her career, Kirk has helped companies transform by fostering a culture of innovation; building high-performing teams; unlocking new growth opportunities; and finding ways to grow revenue and expand margins. She has also led teams that captured over $3.5 billion in savings and value by optimizing operations, streamlining efficiencies and driving strategic investments. Kirk holds an MBA plus additional certifications from Carnegie Mellon and Harvard Business School.

“I am honored and excited to join Exubrion Therapeutics as CEO,” said Kirk. “Synovetin OA is a differentiated technology that has already uniquely transformed the treatment of canine osteoarthritis, delivering real, lasting relief for pets and their families. I’m eager to lead Exubrion Therapeutics into this next phase of growth, not only expanding our reach in the canine market but also unlocking the potential for Synovetin OA to help equine patients and, ultimately, all pets in need of effective osteoarthritis treatment. The opportunity to extend this breakthrough therapy into new areas both domestically and internationally is incredibly exciting, and I look forward to working with the team to make it a reality.”

About Exubrion Therapeutics, Inc.

Exubrion Therapeutics is the developer of Synovetin OA, a breakthrough injectable treatment that provides long-lasting relief for dogs suffering from chronic osteoarthritis. Utilizing proprietary radiotherapeutic technology, Synovetin OA offers targeted, localized therapy to reduce joint inflammation and pain, often providing up to a full year of improved mobility and quality of life with a single treatment. For more information, visit https://activedognow.com/about-exubrion/.   

Studied in canine elbows, Synovetin OA is given by authorized veterinarians. Temporary discomfort in treated joints may occur. Talk to a treating veterinarian near you for more information including what to expect following treatment and visit www.activedognow.com.

Media Contact:
Eric Schreiber, Chief Commercial Officer
(610) 368-0815
eschreiber@exubrion.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/exubrion-therapeutics-appoints-jennifer-kirk-to-board-of-directors-names-her-ceo-302403466.html

SOURCE Exubrion Therapeutics

Continue Reading

Technology

Datavault AI Founder Nathaniel Bradley Sues Board

Published

on

By

WILMINGTON, Del., Nov. 6, 2026 /PRNewswire/ — Lawsuit Alleges Chairman and CFO Brett Moyer Engineered a Weekend Lockout While Keeping a $90–$100 Million Financing Offer From Independent Directors

Datavault AI Founder Nathaniel Bradley Sues Board

Nathaniel Bradley, the founder whose technology became Nasdaq-listed Datavault AI Inc. (NASDAQ: DVLT), today filed a lawsuit in the Delaware Court of Chancery asking the court to declare his contested ouster as CEO void and restore him to office. The complaint alleges that Board Chairman and CFO Brett Moyer “suspended” Bradley without a Board vote, cut off his email, and then rushed through a defective Sunday meeting, all while a $90–$100 million financing lifeline sat on the table.

On October 30, two days after Bradley asked the Board to consider removing Moyer as CFO, Moyer “suspended” Bradley on his own perceived authority. According to the complaint, no Board meeting was held and no written consent was circulated. This was done despite Datavault’s own Bylaws, which give only the full Board the power to remove officers.

The lawsuit further alleges that Moyer and certain unnamed directors shut Bradley out one day after he brought the company a $90–$100 million funding offer that could have substantially improved its financial position. Rather than present the offer, Moyer “suppressed, withheld and concealed” it from the company’s independent directors.

Last night, Bradley released the following statement:

“While I remain confident in Datavault AI’s technology, product offerings, and patent-protected innovations, I strongly dispute the legal validity of the Board’s decision to remove me as President and Chief Executive Officer.

“During my tenure, we increased revenue by more than 1,300% in my first year, alongside record trading volumes, and built the foundation for continued growth. We assembled a portfolio of more than

100 patents and pending applications, including newly issued U.S. patents in data valuation, tokenization, and wireless audio. We launched the Information Data Exchange, NIL Vault, and American Political Exchange, and signed licensing and tokenization agreements that bring real-world assets, from carbon credits to gold, copper, and geothermal energy, onto our platforms. We also completed strategic acquisitions, including API Media Innovations, that expanded our reach into digital twins, sports, and live events. We broadened our strategic partnership network, including with IBM,

ServiceNow, and the Department of Energy, and recruited industry-leading talent to the Datavault cause.

“Innovators are often targeted, and I intend to protect my rights and the interests of the Company and its shareholders. I believe the Board’s action jeopardizes the Company’s ability to realize its full potential.”

Jacob Frenkel, Bradley’s lead counsel and a former SEC enforcement lawyer and federal prosecutor, said:

“The company’s groundbreaking and cutting-edge technologies are a function of Mr. Bradley’s brilliance and vision. As a corporate leader, Mr. Bradley has a long-standing commitment to best practices in corporate governance.”

Mr. Bradley puts his investors first. When you’re out building and innovating and those you think you can trust decide to stage a corporate coup, the only place for relief is in court. Mr. Bradley will continue to fight for the shareholders and against those who put their own interests ahead of the company’s stakeholders.”

Read the full complaint here.

About Nathaniel Bradley:

Nathaniel Bradley is an inventor and technology executive who holds more than 70 patents. He founded and invented AudioEye, founded Intellectual Property Network Inc., and served as CTO of Marathon Patent Group (now Marathon Digital Holdings). In 2021, he founded Data Vault Holdings, whose assets were acquired in December 2024 by WiSA Technologies, the company that became Datavault AI. As CEO, he led the company through partnerships with IBM, Dolby Laboratories, and NYIAX, as well as the acquisition of CompuSystems assets.

View original content:https://www.prnewswire.com/news-releases/datavault-ai-founder-nathaniel-bradley-sues-board-302932495.html

SOURCE Datavault AI Inc

Continue Reading

Technology

County of Sussex, New Jersey Notice of Data Privacy Incident

Published

on

By

NEWTON, N.J., Nov. 6, 2026 /PRNewswire/ — Sussex County Prosecutor’s Office (SCPO) experienced a data privacy event that involved personal information.

On or about August 10, 2026, SCPO received alerts of a disruption to its computer network. Upon this identification, it launched an immediate investigation and engaged outside cybersecurity specialists to assist. The investigation determined that someone accessed its network without authorization between July 15, 2026, and July 22, 2026, and that certain files containing personal information were accessed and may have been taken. That information includes people’s first and last name, Social Security number, and driver’s license or State-issued identification card number. The SCPO has reported the incident to state and federal law enforcement, the New Jersey Cybersecurity and Communications Integration Cell (NJCCIC), and the Office of Attorney General. For more information on this incident, people may contact the call center at (888) 269-1448, Monday through Friday, 9:00 a.m. to 9:00 p.m. EST for further assistance.

Lauren Stinger, Esq.
Lauren.stinger@kennedyslaw.com
Associate Counsel

View original content:https://www.prnewswire.com/news-releases/county-of-sussex-new-jersey-notice-of-data-privacy-incident-302932369.html

SOURCE Kennedys CMK LLP

Continue Reading

Technology

Light AI Announces Resignation of Director and Officer

Published

on

By

VANCOUVER, BC, Nov. 6, 2026 /CNW/ — Light AI Inc. (“Light AI” or the “Company”) (CBOE CA: ALGO (FSE: OHC) (OTCQB: OHCFF), announces that Peter Whitehead has resigned as a director and the Chief Innovation Officer of the Company to pursue other opportunities. The Company would like to thank Mr. Whitehead for his contributions to the Company.

About Light AI Inc. (CBOE CA: ALGO / FSE: OHC / OTCQB: OHCFF)

Light AI Inc. is a healthcare technology company focused on developing artificial intelligence-powered SaMD solutions designed to support rapid, accessible clinical assessment at the point of care. The Company’s core technology, Light AI QuickScan™, is a device-agnostic software platform that applies proprietary artificial intelligence and machine learning algorithms to medical images. The QuickScan™ platform is designed to operate across compatible imaging and computing hardware, providing flexibility for integration into a range of healthcare devices, clinical workflows and care settings without dependence on a single proprietary hardware platform.

ON BEHALF OF THE COMPANY

“John R. Luna”
Chief Executive Officer

For more information, please contact the Company at investors@light.ai or visit https://light.ai/.

Website: https://light.ai/
LinkedIn: LinkedIn/company/Light AI
X (Formerly Twitter): @lightaihealth

SOURCE Light AI Inc.

Continue Reading

Trending